e: info@vacvbtx.com
p: +44 (0)20 809 07585
menu
close
  • Home
  • About us
    • Our vision
    • Our team
  • Our science
    • Our science
    • Publications
  • Our pipeline
  • Our careers
  • News & events
    • News
    • Events
  • Contact us
e: info@vacvbtx.com
p: +44 (0)20 809 07585

Latestnews

Find the latest news coming from VacV Biotherapeutics.
9 Oct 2024
VacV awarded Innovate UK GRANT: Transforming Cancer Therapeutics:

VacV was awarded Innovate UK Grant on 10/09/2024: “Transforming Cancer Therapeutics: Preclinical development of a systemically deliverable oncolytic Vaccinia Virus for treatment of metastatic colorectal cancer” Metastatic (stage 4) colorectal cancer (mCRC) is an almost uniformly lethal disease with only a 14% 5-year survival rate. Current treatment strategies for mCRC are limited and escape form […]

read more +
12 Apr 2024
VacV Biotherapeutics promising biotech startup in cancer immunotherapy

February 2024 – “A promising biotech startup in cancer immunotherapy” Labiotech Cancer vaccines: 10 biotech companies that have changed the game

read more +
26 Oct 2022
VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic

VacV Biotherapeutics (“VacV” or “the Company”), a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its promising pipeline of pre-clinical assets with best-in-class potential, towards the clinic.

read more +
load more +
e: info@vacvbtx.com
p: +44 (0)20 809 07585
  • About us
  • Our science
  • Publications
  • Our pipeline
  • Our careers
  • News
  • Events
  • Contact us
© 2022 VacV Biotheraputics (UK) Ltd. | Design and development by TIG
Privacy Policy